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Abstract
Objectives: To report the outcome of all robot-assisted laparoscopic radical prostatectomy (RALP) in the public
health care system in Hong Kong.
Patients and Methods: All patients who underwent RALP in the public health care system with at least 1 year of
follow-up were evaluated. Data analysis included age, body mass index, preoperative prostate-specific antigen
(PSA) level, D’Amico risk category, operative details, pathologic stage, follow-up continence, potency, and
biochemical recurrence.
Results: Between 2005 and 2009, 235 patients underwent RALP, with a mean age of 66.4 – 5.9 years and a mean
preoperative PSA level of 11.0 – 10.5 ng/mL. Complications were 16 (7%) in total. There were 176 (74.9%)
patients with pT2 disease and 55 (23.4%) patients with pT3 disease. The overall rate of positive surgical margins
(PSM) was 20.7%. At postoperative 12 months, 72.5% of the patients were pad free. For those 83 preoperative
potent patients having nerve-sparing surgery, the overall trifecta rate at 12 months was 37.3%. Multivariate
analysis identified that pathologic T staging was significantly associated with PSM, with an odds ratio (OR) of
7.884 (95% confidence interval [CI]: 3.576–17.379; P < 0.001) for the pT3 group compared with the pT2 group.
When comparing D’Amico medium- and high-risk categories with low-risk categories, they were found to be
significantly associated with biochemical failure (medium- compared with low-risk: OR = 3.536, 95% CI: 1.253–
10.173, P = 0.016; high- compared with low-risk: OR = 10.214, 95% CI: 2.958–35.274, P< 0.001).
Conclusions: Ourdatademonstrate the feasibility, safety, and efficacy ofRALP in low-to-intermediate volume centers.
Our early oncologic outcomes were significantly correlated with pathologic stage and D’Amico risk stratification.
Introduction
Prostate cancer is the second most common cancerin the world, with a world age-standardized rate of 28 per
100,000.1 While the Western nations have a higher incidence
of prostate cancer, it is increasing rapidly in Asian countries
because of a more westernized lifestyle.2 In Hong Kong,
prostate cancer is currently the third most common cancer in
men and ranks fifth in cancer mortality.3
For localized prostate cancer, radical prostatectomy (RP)
remains the standard for long-term cure.4 In an effort to re-
duce morbidity of open RP, Schusessler and associates5 first
described a minimally invasive surgical approach to treat
patients with prostate cancer with laparoscopic RP in 1997.
The subsequent introduction of the da Vinci Surgical System
(Intuitive Surgical, Sunnyvale, CA) paved the breakthrough
in minimally invasive prostatectomy. With the promise of
improved ergonomics and a shortened learning curve that
accompany the da Vinci Surgical System, robot-assisted lap-
aroscopic radical prostatectomy (RALP) is rapidly gaining
acceptance in the urologic community.6
RALP is blossoming in Asia as well as in theWest. Since the
implementation of robotics in the Asian region, a dramatic
increase in the number of RALP has been seen.7 This ‘‘halo
effect,’’ as referred to by Sung and colleagues,8 contributes to
the evolution of robotic surgical techniques into maturity in
the region. Hong Kong had its first robotic system installed in
20059 and is among the first few cities in Asia that acquired
such technology. While most of the RALP in the West are
performed in the context of a private insurance scheme, the
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majority of robot-assisted prostatectomies in Hong Kong are
performed in the public sector. We report the outcome of all
RALP in the public health care system in Hong Kong since its
launch in 2005.
Patients and Methods
There are a total of five da Vinci Surgical Systems for
clinical use in Hong Kong. Four of them are being used in the
public sector in four different hospitals. Theywere introduced
between 2005 and 2009. We evaluated all patients who un-
derwent RALP in the public health care system with at least 1
year of follow-up.
All surgeons who were involved in the series were profi-
cient in laparoscopic surgery, and some had previous robotic
experience in other localities. The majority of cases were
performed using the six-port technique. All adopted the
transperitoneal approach. The general criteria for considering
a nerve-sparing procedure were potent patients in the low to
moderate D’Amico risk category. The final decision also in-
volved patient preference and the intraoperative condition,
Most of the nerve-sparing procedures were performed with
the interfascial technique. A few cases were performed in-
trafascially. The vesicourethral anastomosis was created us-
ing continuous running suture as originally described by van
Velthoven and coworkers.10
Data collection included age, body mass index (BMI), pre-
operative prostate-specific antigen (PSA) level, D’Amico risk
category,1 operative details, postoperative course, pathologic
stage, follow-up continence, potency, and biochemical recur-
rence. Follow-up protocols across the four centers were sim-
ilar. Clinical outcome of patients at postoperative 3, 6, and 12
months were reviewed. Continence status was classified into
four groups: (1) Pad free, (2) use of one pad for security or
occasional stress incontinence, (3) two to three pads per day,
and (4) four or more pads per day. Potency was defined as the
ability to achieve and maintain satisfactory erections firm
enough for sexual intercourse for more than 50% of times,
with or without the use of oral phosphodiesterase type 5 in-
hibitors. Biochemical recurrence was defined as two consec-
utive values of PSA> 0.2 ng/mL.
Descriptive statistics were used to characterize the clinical
characteristics of the study cohort. Univariate and multivari-
ate logistic regression analyses were performed to identify
clinical covariates that were significantly associated with
surgical margin status, erectile function status, continence
status, and biochemical recurrence. Odds ratios (ORs) and
their associated 95% confidence interval (CI) were estimated.
P values< 0.05 were considered statistically significant. SPSS
software package version 17 (SPSS Inc, Chicago, IL) was used
for all calculations.
Results
Between November 2005 and December 2009, 235 consec-
utive patients underwent RALP in the public sector in Hong
Kong. Patient characteristics are outlined in Table 1. Median
follow-up time was 20 months. The majority of the cohort
belonged to the D’Amico low-risk category (65%). About half
of the patients were potent preoperatively.
Table 1 summarizes the perioperative parameters. Among
the 235 cases, 64 cases underwent pelvic lymphadenectomy.
Mean operative time was 362– 124mins. Mean estimated
blood loss was 626 – 657mL. Four patients needed open
conversion in our series; two of the procedures were con-
verted for hemostasis purposes, and the other two because of
the dense adhesion encountered during dissection. Mean
hospital stay and mean catheter time were 7– 4 days and
13– 6 days, respectively.
Complications were 16 (7%) in total and comprised 6
anastomotic leakages (2.6%), 3 deep vein thrombosis (DVT)
(1.3%), 3 wound infection (1.3%), 1 rectal perforation (0.4%), 1
urethral stricture (0.4%), 1 lymphocele (0.4%), and 1 pulmo-
nary embolism (0.4%). The patient with pulmonary embolism
was about to be discharged when a sudden postoperative
event developed on postoperative day 9 and he succumbed.
Histopathologic analysis of the RALP specimen found a
mean prostate weight of 49.4 – 20.8 g (Table 2). There were 176
(74.9% ) patients with pT2 disease while 55 (23.4%) patients
had pT3 disease. The overall rate of positive surgical margin
(PSM) was 20.7%. In the subcategorical analysis review, pT2
patients and pT3 patients had a PSM rate of 12% and 41%,
respectively. At postoperative 12 months, 72.5% of the pa-
tients were pad-free (Table 3). For those 83 preoperative
Table 1. Patient Characteristics
and Perioperative Parameters
Parameter Value
Patients (n) 235
Mean age, y – SD 66.4 – 5.9
Mean BMI, kg/m2– SD 24.8 – 3.2
Mean PSA, ng/mL – SD 11.0 – 10.5
Clinical stage
cT1a (n) 1 (0.4%)
cT1b (n) 4 (1.7%)
cT1c (n) 175 (74.5%)
cT2a (n) 39 (16.6%)
cT2b (n) 8 (3.4%)
cT2c (n) 8 (3.4%)
Preoperative total Gleason score
6 (n) 172 (73.2%)
7 (n) 40 (17.0%)
8 (n) 14 (6.0%)
9 (n) 4 (1.7%)
D’Amico risk category
Low (n) 152 (65%)
Medium (n) 62 (26%)
High (n) 20 (9%)
Preoperative potent patients (n) 132 (56%)
Mean follow-up duration, mos – SD 24– 12
Mean operative time, min – SD 362– 124
Mean blood loss, mL– SD 626– 657
Conversion to open (n) 4 (1.7%)
Mean catheter in-situ time, d – SD 13 – 6
Mean hospital stay, d – SD 7 – 4
Complications
Anastomotic leakage (n) 6 (2.6%)
Deep vein thrombosis (n) 3 (1.3%)
Wound infection (n) 3 (1.3%)
Rectal perforation (n) 1 (0.4%)
Pulmonary embolism (n) 1 (0.4%)
Urethral stricture (n) 1 (0.4%)
Lymphocele (n) 1 (0.4%)
Mortality 1 (0.4%)
SD = standard deviation; BMI=body mass index; PSA=prostate-
specific antigen.
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potent patients who underwent nerve-sparing surgery (in-
cluding unilateral nerve-sparing RALP), 31 (37.3%) patients
remained potent at postoperative 12 months (Table 4). In the
cohort of these 83 patients, the overall trifecta rate (pad free,
potent, no biochemical recurrence) at 12 months was 37.3%.
Among the 235 cases, 29 (12.3%) patients were given ad-
juvant therapies. These adjuvant therapies included radio-
therapy (n = 18), antiandrogen (n = 1), surgical (n = 4), and
medical castration (n = 6).
While no correlation was found between nerve sparing and
PSM, multivariate analysis with logistic regression identified
that pathologic T staging was significantly associated with
PSM, with an OR of 7.884 (95% CI: 3.576–17.379; P< 0.001) for
pT3 group compared with the pT2 group (Table 5). There was
a negative correlation between prostate specimen weight and
PSM, with an OR of 0.972 (95%CI: 0.950–0.994; P = 0.013).
D’Amico risk stratification had an implication on biochemical
recurrence. When comparing medium- and high-risk cate-
gories with low-risk categories, they were found to be
significantly associated with biochemical failure (medium-
compared with low-risk: OR = 3.536, 95%CI: 1.253–10.173,
P = 0.016; high- compared with low-risk: OR= 10.214, 95%CI:
2.958–35.274, P < 0.001).
Discussion
Since the first robot-assisted laparoscopic radical prosta-
tectomy performed by Binder and Kramer12 in May 2000,
RALP has become a popular approach for the management of
prostate cancer in many regions. While the da Vinci robotic
system offers several advantages for surgeons, including 10x
magnification with three-dimensional stereoscopic optics and
end-of-wrist instrument with 7 degrees of freedom in range of
motion, its expensive implementation cost has been a concern
to many centers.13 Contrary to other regions, the four robotic
surgery systems in the public sector in Hong Kong were do-
nated initially as charity and run subsequently by receiving
support from the public health care system. Robotic surgery in
Hong Kong thus carries a low price tag for patients, although
not necessarily for the whole health care system.
Oncologic outcome would definitely be one of the main
interests during the evaluation of any cancer surgery. The
parameters for such assessment include overall survival,
disease-specific survival, and biochemical recurrence-free
survival, which is commonly defined as a PSA level < 0.2 ng/
mL. Not all of these parameters are applicable, however, in
the comparison between an RALP series and an open RP se-
ries at this junction, where the latter had 15-year outcome data
available.14 Biochemical recurrence and surgical margin sta-
tus are thus often used as surrogates for cancer control when
evaluating oncologic efficacy.
The largest series of RALP to date was reported by Badani
and colleagues15 from the Henry Ford Center in Detroit. It
involved 2766 patients with a follow-up of up to 5 years. In
their series, they reported a PSA recurrence of 7.27%. Among
pT2 and pT3 patients, the rates of PSM were 13% and 35%,
respectively. Patel and associates16 evaluated a single-
surgeon experience of 1500 consecutive RALP, and reported a
PSM rate of 4% for pT2 and 34% for pT3
.
Our series had a PSM rate of 12% for pT2 and 41% for pT3,
and an overall PSM rate of 20.7%. These figures fell within the
range of previous reports in the literature, which showed a
mean overall PSM rate of 15.2% (range of means 9.3%–33%), a
mean PSM rate for pT2 of 9.6% (range of means 2.5%–18%),
and amean PSM rate for pT3 of 37.1 % (range ofmeans 20.9%–
53.8%).17
A higher T stage of the tumor has been implicated to have a
higher risk for PSM in the open RP series.18 There were very few
reports in the literature on this subject for RALP, however.
Weizer and coworkers19 reviewed a cohort of 633 patients,
consisting of both openprostatectomyandRALP. It showed that
patients with a lower pathologic stage (pT2) had a lower risk of
PSM compared with patients with pT3 or more disease. In a
study byHam and associates,20 the authors noted that therewas
a significant difference in PSM rate between clinically localized
and locally advanced prostate cancer (48% vs 59% respectively,
P<0.001). Our finding of pathologic T stage being significantly
associated with PSM rate in RALP would complement the
Table 2. Oncologic Outcome
Parameter Value
Mean prostate specimen weight, g – SD 49.4 – 20.8
Pathological T stage (n)
T2 (n) 176 (74.9%)
T3 (n) 55 (23.4)
Tx (n) 4 (1.7%)
Prostate specimen Gleason score
6 (n) 144 (61.3%)
7 (n) 63 (26.8%)
8 (n) 15 (6.4%)
9 (n) 6 (2.6%)
Positive surgical margin (n) 47 (20.7%)
T2 (n) 21
T3 (n) 26
Overall biochemical recurrence (n) 22 (9.4%)
D’Amico low risk (n) 7
D’Amico medium risk (n) 9
D’Amico high risk (n) 6
Mean biochemical recurrence time,
months – SD
18 – 11
SD= standard deviation.
Table 3. Continence Outcome
3mos 6mos 12mos
Pad-free (n) 98 (42.4%) 138 (60.8%) 166 (72.5%)
Occasional
incontinence (n)
60 (26.0%) 35 (15.4%) 22 (9.6%)
2–3 pads per day (n) 43 (18.6%) 35 (15.4%) 24 (10.5%)
4 or more pads
per day (n)
30 (13.0%) 19 (8.4%) 17 (7.4%)
Table 4. Erectile Function Outcome
of Preoperative Potent Patients
Parameter Value
Preoperative potent patients undergoing
nerve-sparing RALP (n)
83
Postoperative 1-year potent patients (n) 31 (37.3%)
Number of patients on PDE5 inhibitor (n) 45 (54.2%)
RALP= robot-assisted laparoscopic prostatectomy; PDE5=phos-
phodiesterase type.
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current reports in the literature. Furthermore, we demonstrated
that D’Amico risk stratificationwas associatedwith biochemical
failure in our cohort. The low-risk groupwas significantly better
than those of medium- and high-risk groups. While this sup-
ports the D’Amico risk stratification as an effective predictor of
early outcomes after RALP, our study is among the first few to
evaluate the significance of risk stratification on early outcomes
in a robotic cohort.
Besides complete removal of the cancer, recovery of potency
and urinary continence are the other two long-term goals of RP.
Potency is not easy to evaluate because there is significant var-
iation in the literature as to the definition of potency after RP. A
systemic review reported that at 12-month follow-up, potency
rates ranged from 20% to 97%.21 Our series reported a 12-month
potency rate of 37.3%. While a lack of universal potency defi-
nition may render it difficult to compare our data with other
cohorts, a few factorsmay account for our relatively lowpotency
rate. Mulhall and colleagues22 demonstrated that postoperative
early penile rehabilitation significantly increased the likeliness of
achieving functional erections. The investigation by Rogers and
coworkers23 found that youngermenhad earlier return of sexual
function and higher overall potency rates at 1 year after RALP.
In our locality, an early penile rehabilitation program is not yet
prevalent. In addition, when compared with many contempo-
rary RALP series, which had a mean or median age range from
56.3 to 63.2 years, the mean age of our patients was older.17
These characteristics may have an influence on our potency re-
sults. Concerning urinary continence, our series demonstrated
that 12 months after RALP, 80.1% of the patients needed no
absorbent pads or the use of 1 pad only for security. This result is
in line with many other RALP series, which reported a conti-
nence rate of 70% to 97% at 12 months of follow-up.17
There was onemortality in our robot-assisted prostatectomy
cohort. Pulmonary embolism (PE) developed in the patient on
postoperative day 9. Postmortem examination did not reveal
any DVT. In a multi-institutional study, the incidence of ve-
nous thromboembolism among 5951 patients who were trea-
tedwith laparoscopic RP,with orwithout robot assistance,was
examined.24 Symptomatic DVT or PE developed in 31 patients
(0.5%). Among these patients, four had PE without identified
DVT. In their cohort, two patients died of PE. While this study
focused on symptomatic thromboembolic events, Yee and
colleagues25 reported the findings of silent thromboembolic
events. In that series, routine bilateral lower limb Doppler ul-
trasonographywas performed for consecutive 65 patients after
RALP on postoperative day 5. None of the patients had
symptomatic DVT, but 1 (3.1%) patient was found to have
above-knee venous thromobosis and seven (21.9%) patients
were found to have below-knee venous thrombosis on ultra-
sonographic examination. Both of these studies concluded that
the incidence of symptomatic thromboembolic events was low
after minimally invasive RP, and disease stage and pelvic
lymph node dissection were not significant factors associated
with thromboembolic events. Furthermore, data from the
multi-institutional study do not support the administration of
prophylactic heparin to all patients undergoing RP, in view of
its minimal benefit with an increased complication rate. Based
on current evidence, such judicious use of heparin is being
adopted by the authors of this article.
The concurrent assessment of cancer-free, continence, and
potency was termed ‘‘trifecta,’’ after Salomon and cowork-
ers26 first reported their functional and oncologic outcomes
combined in their series of open, laparoscopic, and perineal
prostatectomy. There were very scarce reports of trifecta
outcome in RALP patients in the literature. Such an account
was first made by Shikanov and associates,27 who reported a
trifecta rate of 44% at 12 months after RALP. In our series, the
trifecta rate is 37.3% at 12 months. As previously illustrated,
study designs and criteria for continence and potency often
lack consistency. This may prevent us from directly compar-
ing our results with other larger series—for example, Patel
and colleagues,28 who achieved a trifecta rate of 86% at 12
months. Furthermore, the larger RALP series in the literature
were often the report of a few high-volume surgeons.15,27,28
While some suggested that the learning curve was adequately
developed after 25 to 45 cases of RALP,6,16,29 there is evidence
that implied that the learning curve issue is much more
complex, and individual surgeon results continue to improve
up to 100 cases and beyond.16,30 Because only one center had
performed more than 100 cases of RALP in our series, an
accurate and comprehensive observation on the matter of
learning curve in our series may be difficult.
Whenwe reviewed the operative time, all except one center
had a decrease in mean operative time when comparing the
initial 50% of the cases with the later 50%. This may serve as
an indicator of showing a gradual mastering of the technique
on the way and may imply being able to overcome the
learning curve when cases accumulate. Although the im-
plementation of the da Vinic robotic system is gaining pop-
ularity rapidly, most urologists performed much fewer
prostatectomies than those high-volume surgeons quoted in
the literature.31 Thus, our account of RALP may be more
applicable to most institutions, which belong to the category
of low-to-moderate volume center.
While the cost of robotic surgery is one of the issues that
concerns health institutes, surgeons, and patients, we have
not explored this aspect in the current study. In terms of cost
analysis, there are two aspects to be considered. On the one
Table 5. Multivariate Analysis of Perioperative Parameters on Positive Surgical
Margins and Biochemical Recurrence
Factors OR 95% CI P value
Positive surgical margins T stage 7.884 3.576, 17.379 < 0.001
Operative time 1.004 1.001, 1.008 0.012
Prostate specimen weight 0.972 0.950, 0.994 0.013
Biochemical recurrence D’Amico low risk 1.000(ref )
D’Amico medium risk 3.536 1.253, 10.173 0.016
D’Amico high category 10.214 2.958, 35.274 < 0.001
OR= odds ratio; CI = confidence interval.
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hand, there are the additional implementation cost, mainte-
nance cost, consumables cost, and maybe a longer operative
time in certain aspects. These factors have also been elabo-
rated by Barbash and associates.32 On the other hand, the key
attributes of robotic surgery are increased precision, minia-
turization, articulation beyond normal manipulation, and
three-dimensional magnification. These would contribute to a
reduction in the length of hospital stay, postoperative com-
plications, blood loss, and time off work. When these im-
provements are accounted for, there may be a considerable
savings to hospitals and society as a whole, offsetting the
additional cost. Because of the complexity of the model, this
may be beyond the scope of the current study, and we would
hope that a separate investigation could be carried out on the
subject of RALP cost analysis.
There are certain limitations of the present study. First, being
a retrospective study, it was difficult to have a standardized
follow-up protocol and surgical technique. Different surgeons
in the cohort performed RALP with slightly different modifi-
cations. Such heterogeneity in techniquemay cloud the picture.
In addition, the assessment of potency and urinary continence
was made by patient-surgeon interviews. This may not corre-
late with patient self-assessments of health-related quality of
life. Furthermore, the mean follow-up was relatively short
when compared with the open prostatectomy series. This may
affect trifecta outcomes given that with time, the biochemical
recurrence rate increases, while continence and potency may
improve. As the robotic technique becomes more established,
we hope that longer-term data would be available.
Conclusions
We report a 37.3% rate of trifecta at 12 months after RALP
in 235 patients. Our early oncologic outcomes were signifi-
cantly correlated with pathologic stage and D’Amico risk
stratification and appear to be similar to those in larger RALP
series. Our data demonstrate the feasibility, safety, and effi-
cacy of RALP in low-to-intermediate volume centers.
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Abbreviations Used
BMI¼ radical prostatectomy
CI¼ confidence interval
DVT¼deep vein thrombosis
OR¼ odds ratio
PE¼pulmonary embolism
PSA¼prostate-specific antigen
PSM¼positive surgical margins
RALP¼ robot-assisted laparoscopic radical
prostatectomy
RP¼ radical prostatectomy
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